Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  2012-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70474-6PMID 23084521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

  2012cited by this paper
• A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

  2012cited by this paper
• Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma.

  2012cited by this paper
• Progression-free survival ratio as end point for phase II trials in advanced solid tumors.

  2011cited by this paper
• TP53 mutations in human cancer: database reassessment and prospects for the next decade.

  2011cited by this paper
• Automated Brightfield Dual-Color In Situ Hybridization for Detection of Mouse Double Minute 2 Gene Amplification in Sarcomas

  2011cited by this paper
• Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling

  2011cited by this paper
• Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region

  2010cited by this paper
• The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

  2010cited by this paper
• Well-differentiated and dedifferentiated liposarcomas

  2010cited by this paper
• Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

  2009cited by this paper
• The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• Differential sensitivity of liposarcoma subtypes to chemotherapy.

  2005cited by this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

  2003cited by this paper
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone

  2002cited by this paper
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

  2002cited by this paper
• Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas

  2001cited by this paper
• p53 and human cancer: the first ten thousand mutations.

  2000cited by this paper
• Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

  2000cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function

  1996cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper

• Colossal well-differentiated liposarcoma of the small bowel mesentery: A case report

  2026cites this paper
• Cellular senescence in cancer: Friend or fraud?

  2026cites this paper
• Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope

  2026cites this paper
• MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib‑resistant chronic myeloid leukemia cells

  2025influential citation
• A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.

  2025cites this paper
• A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.

  2025cites this paper
• Identification of Potent Cell Penetrating, Nontoxic Peptides for Inhibiting MDM2–p53 Interactions: Characterization of Anticancer Peptides via Molecular Dynamics Simulations

  2025cites this paper
• Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction

  2025influential citation
• A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation.

  2025cites this paper
• The evolution of Nutlins as p53-MDM2 inhibitors

  2025influential citation
• Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group.

  2025cites this paper
• MDM2 inhibitors in sarcomas: results and next steps

  2025cites this paper
• Senolytic treatment for low back pain

  2025cites this paper
• Ferroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma

  2025cites this paper
• MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions

  2025cites this paper
• Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies

  2025cites this paper
• MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

  2025influential citation
• MDM2 as a therapeutic target in advanced biliary tract cancers

  2025cites this paper
• A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer.

  2025cites this paper
• Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema.

  2025cites this paper
• Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling

  2024cites this paper
• P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds.

  2024cites this paper
• MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis

  2024cites this paper
• Explainable machine learning predicts survival of retroperitoneal liposarcoma: A study based on the SEER database and external validation in China

  2024cites this paper
• Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

  2024cites this paper
• Lymph node myeloid sarcoma with TP53‑associated myelodysplastic syndrome: A case report

  2024cites this paper
• Comparative Molecular Docking of Apigenin and Luteolin Versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies

  2024cites this paper
• Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma

  2024cites this paper
• Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature

  2024cites this paper
• Cellular senescence and SASP in tumor progression and therapeutic opportunities

  2024cites this paper
• Lessons learned from 20 years of preclinical testing in pediatric cancers

  2024cites this paper
• Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing

  2024cites this paper
• E3 ligases and DUBs target ferroptosis: A potential therapeutic strategy for neurodegenerative diseases.

  2024cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• New targeted therapies in liposarcoma: state of art and future perspectives

  2024cites this paper
• Dedifferentiated liposarcoma of the spermatic cord

  2024cites this paper
• An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies

  2024cites this paper
• Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy

  2024cites this paper
• MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

  2024cites this paper
• The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer

  2024cites this paper
• Molecular characteristics and systemic treatment options of liposarcoma: A systematic review.

  2024cites this paper
• Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant.

  2024cites this paper
• Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.

  2024cites this paper
• Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations

  2024cites this paper
• MDM2: current research status and prospects of tumor treatment

  2024cites this paper
• Novel Therapeutics in Soft Tissue Sarcoma

  2024cites this paper
• p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response

  2024cites this paper
• Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

  2023cites this paper
• Computational-based drug design of novel small molecules targeting p53-MDMX interaction

  2023cites this paper
• Transcription Factors and Cancer

  2023cites this paper
• p53 Regulates the Extent of Fibroblast Proliferation and Fibrosis in Left Ventricle Pressure Overload

  2023cites this paper
• Senolytic Drugs: Implications for Clinical Practice

  2023cites this paper
• MDM2‐Targeting Reassembly Peptide (TRAP) Nanoparticles for p53‐Based Cancer Therapy

  2023cites this paper
• Targeted MDM2 degradation reveals a new vulnerability for p53 inactivated triple negative breast cancer.

  2023cites this paper
• Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

  2023cites this paper
• Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study.

  2023cites this paper
• The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

  2023cites this paper
• MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

  2023cites this paper
• MDM2 Amplification Status in a Cohort of Well-Characterized Myxofibrosarcoma: A Clinicopathologic Analysis of 22 Tumors

  2023cites this paper
• Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?

  2023cites this paper
• The roles of ubiquitination in AML

  2023cites this paper
• Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells

  2023cites this paper
• P53 together with ferroptosis: a promising strategy leaving cancer cells without escape

  2023cites this paper
• Small molecules targeting protein–protein interactions for cancer therapy

  2023cites this paper
• Multimodal Imaging and Management of a Metastatic Cardiac Intimal Sarcoma

  2023cites this paper
• Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

  2023cites this paper
• Small-molecule correctors and stabilizers to target p53.

  2023cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• The Use of Hydrogels for the Treatment of Bone Osteosarcoma via Localized Drug-Delivery and Tissue Regeneration: A Narrative Review

  2023cites this paper
• FAM193A is a positive regulator of p53 activity

  2023cites this paper
• Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway

  2023influential citation
• A metabolic crosstalk between liposarcoma and muscle sustains tumor growth

  2023cites this paper
• Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation

  2023cites this paper
• CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells

  2023cites this paper
• New targeted treatments for advanced sarcomas

  2023cites this paper
• MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.

  2023cites this paper
• Update on immunohistochemistry in bone and soft tissue tumors: Cost-effectively replacing molecular testing with immunohistochemistry.

  2023cites this paper
• A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

  2023cites this paper
• Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

  2022influential citation
• Established and Experimental Systemic Treatment Options for Advanced Liposarcoma

  2022cites this paper
• Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.

  2022cites this paper
• The roles of ubiquitination‐mediated intrinsic apoptotic signalling in cancer therapy

  2022cites this paper
• Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

  2022cites this paper
• Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.

  2022cites this paper
• Personalised pharmacotherapy options for soft tissue sarcomas

  2022cites this paper
• Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward

  2022cites this paper
• The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis

  2022cites this paper
• First and further-line multidisciplinary treatment of retroperitoneal sarcomas

  2022cites this paper
• Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.

  2022cites this paper
• Biochemical, Molecular and Histopathological Studies on Malathion Toxicity on Some Vital Organs of Male Rats

  2022cites this paper
• The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.

  2022cites this paper
• Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

  2022cites this paper
• Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

  2022cites this paper
• PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response

  2022cites this paper
• Drugging p53 in cancer: one protein, many targets

  2022cites this paper
• Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

  2022cites this paper
• Therapeutic Strategies to Activate p53

  2022cites this paper
• Small-molecule MX-C2/3 suppresses non-small cell lung cancer progression via p53 activation.

  2022cites this paper
• Tryptophan association in water driven by charge-transfer interactions with electron-deficient aromatic haptens.

  2022cites this paper
• Probing Alterations in MDM2 Catalytic Core Structure Effect of Garcinia Mangostana Derivatives: Insight from Molecular Dynamics Simulations

  2022cites this paper